Status:
COMPLETED
Dosimetry Using a CZT-camera Following LUTATHERA® Therapy
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Dosimetry
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to assess the consistency between a dosimetry protocol using a large field of view CZT-camera and the dosimetry protocol used for recordings acquired with a conventional camer...
Detailed Description
177Lu-DOTATATE has been proven to be an effective therapy for treatment of neuroendocrine tumors. Treatment with \[177Lu\]-DOTA-TATE consists of 4 cycles, with an infusion of 7.4 GBq (200mCi) every 8 ...
Eligibility Criteria
Inclusion
- Major adult subject
- ECOG ≤ 2
- Subject receiving treatment with Lutathera®
- Subject having given written, free and informed consent
- Affiliation to a social security scheme
Exclusion
- Contraindication to treatment with Lutathera®
- Subject referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the public health code.
- Pregnant woman, parturient or nursing mother.
- Subject with a legal protection measure (guardianship, curatorship, safeguard of justice).
- Subject unable to express consent.
- Subject deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under Articles L. 3212-1 and L.3213-1
Key Trial Info
Start Date :
November 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 24 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04467567
Start Date
November 27 2020
End Date
July 24 2023
Last Update
February 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chru Nancy
Vandœuvre-lès-Nancy, France, 54511